Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
55 Results for "
T7
" in MedChemExpress (MCE) Product Catalog:
Products (55)
55 Results for "T7" in MCE Product Catalog:
Cat. No.: HY-171632
CAS No.: 870997-99-2
Research Areas:
2'-(2-Nitrobenzyl)-ATP is an rATP analog. 2'-(2-Nitrobenzyl)-ATP acts as a transcription terminator, inhibiting further RNA chain elongation by T7 RNA polymerase .
Cat. No.: HY-171632A
Research Areas:
2'-(2-Nitrobenzyl)-ATP trisodium is a rATP analog. 2'-(2-Nitrobenzyl)-ATP trisodium acts as a transcription terminator, inhibiting further RNA chain elongation by T7 RNA polymerase .
Cat. No.: HY-131817
CAS No.: 76310-16-2
Target:
Research Areas:
5'-GMPS is an analogue of 5'-GMP and a substrate, competitive inhibitor or regulator of enzymes that interact with 5'-GMP. 5'-GMPS is suitable as a primer of RNA synthesis by T7 RNA polymerase .
Cat. No.: HY-164193
Target:
Research Areas:
m7(3'AcmG)(5')ppp(5')(2'OMeA)pU ammonium is a cap analogue that requires the T7 promoter with AU as the start sequence for mRNA synthesis.
Cat. No.: HY-P11918
CAS No.: 2350190-98-4
Target:
Research Areas:
D-T7 is a transferrin receptor (TfR) binding peptide that mediates brain-targeted delivery. D-T7 acts as a penetration enhancer and uptake promoter for nanoparticles in glioma tissues and target cells. D-T7 can be used in glioma research .
Cat. No.: HY-P11919
CAS No.: 2422045-23-4
Target:
Research Areas:
D-T7-cys is a D-T7 (HY-P11918) peptide with a C-terminal D-cysteine (HY-W018555). Nanoparticles modified with D-T7-cys serve as effective carriers for the delivery of compounds targeting the transferrin receptor (TfR). D-T7-cys reacts with DOX-SS-Pyr to form the DT7-SS-DOX conjugate. D-T7-cys is applicable to research related to glioma, autism spectrum disorder, glioblastoma, hepatocellular carcinoma, and lung cancer .
Cat. No.: HY-184575A
Cat. No.: HY-184552
Target:
Research Areas:
DOPE-PEG1000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DOPE-PEG1000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184552A
Target:
Research Areas:
DOPE-PEG2000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DOPE-PEG2000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184552B
Target:
Research Areas:
DOPE-PEG3400-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DOPE-PEG3400-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184552C
Target:
Research Areas:
DOPE-PEG5000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DOPE-PEG5000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184564A
Target:
Research Areas:
DPPE-PEG2000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dipalmitoylphosphatidylethanolamine (DPPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DPPE-PEG2000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184565A
Target:
Research Areas:
DSG-PEG2000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: distearoylglycerol (DSG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DSG-PEG2000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184570
Target:
Research Areas:
DMG-PEG1000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DMG-PEG1000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184570A
Target:
Research Areas:
DMG-PEG2000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DMG-PEG2000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184570B
Target:
Research Areas:
DMG-PEG3400-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DMG-PEG3400-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-184570C
Target:
Research Areas:
DMG-PEG5000-T7 is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and T7 peptide (HAIYPRH) as the terminal targeting/functional ligand. DMG-PEG5000-T7 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against transferrin receptor (TfR/CD71) on the surface of cancer cells and brain endothelial cells.
Cat. No.: HY-173065
CDK9-IN-36 (Compound T7) is a potent, selective and metabolically stable CDK9 inhibitor with an IC50 value of 1.2 nM. CDK9-IN-36 effectively suppresses cell proliferation, reduces colony formation, and induces apoptosis in Osimertinib (HY-15772)-resistant NSCLC cells by downregulating Mcl-1. CDK9-IN-36 also demonstrates antitumor efficacy in a tumor xenograft model .
Cat. No.: HY-131740A
Synonyms: C7dATP sodium
Research Areas:
2'-Deoxytubercidin 5'-triphosphate sodium (C7dATP sodium) is a deoxyadenosine triphosphate (dATP) analog that serves as a substrate for DNA polymerases. 2'-Deoxytubercidin 5'-triphosphate sodium eliminates Hoogsteen base-pairing capacity and weakens base-stacking interactions; it is recognized and incorporated into nascent DNA strands by DNA polymerases such as Klenow and T7; it reduces DNA electrophoresis compression artifacts; it is effectively degraded by apyrase, thereby lowering the enzyme product inhibition effect caused by dATPaS. 2'-Deoxytubercidin 5'-triphosphate sodium reduces abnormal electrophoretic mobility caused by compression of G or A residues and is used to improve the quality of DNA sequencing data .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
